The Prospect of Improving Pancreatic Cancer Diagnostic Capabilities by Implementing Blood Biomarkers: A Study of Evaluating Properties of a Single IL-8 and in Conjunction with CA19-9, CEA, and CEACAM6

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Oct 26

PMID 39457656

Authors

Tomas Bukys

Benediktas Kurlinkus

Audrius Sileikis

Dalius Vitkus

Affiliations

Soon will be listed here.

Abstract

: This study aims to evaluate the possible clinical application of interleukin 8 (IL-8) as a single biomarker and its capabilities in combination with carbohydrate antigen (CA19-9), carcinoembryonic antigen (CEA), and carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) as diagnostic and prognostic tools for pancreatic ductal adenocarcinoma (PDAC). : A total of 170 serum samples from patients with PDAC (n = 100), chronic pancreatitis (CP) (n = 39), and healthy individuals (n = 31) were analysed. IL-8 and CEACAM6 were measured by an enzyme-linked immunosorbent assay (ELISA). CA19-9 and CEA were determined by chemiluminescent microparticle immunoassay, and bilirubin was quantified using a diazonium salt reaction. Receiver operating characteristic curve analysis, logistic regression, and Kaplan-Meier analyses were performed to evaluate the properties of a single IL-8 and in combination with other biomarkers. : The concentrations of IL-8 were statistically significantly higher in the PDAC group compared to the CP and control groups. Heterogeneous levels of IL-8 correlated with PDAC stages ( = 0.007). IL-8 had good and satisfactory diagnostic efficacy in differentiating PDAC from controls (0.858; < 0.001) and patients with CP (0.696; < 0.001), respectively. High and low expressions of IL-8 were not significantly associated with overall survival (OS) or disease-free survival (DFS). A combination of IL-8, CEACAM6, and CA19-9 reached the highest AUC values for differentiating PDAC from the control group. The best classification score between PDAC and the control group with CP patients was obtained by merging IL-8 and CA19-9 (0.894; < 0.001). : These results provide compelling evidence of IL-8 as a promising diagnostic biomarker. Nonetheless, due to the high complexity of PDAC, only the conjunction of IL-8, CA19-9, and CEACAM6 integrates sufficient diagnostic capabilities.

References

Kim S, Choi G, Jou S . Pancreas Ductal Adenocarcinoma and its Mimics: Review of Cross-sectional Imaging Findings for Differential Diagnosis. J Belg Soc Radiol. 2018; 102(1):71. PMC: 6208287. DOI: 10.5334/jbsr.1644. View

Li K, Yuan J, Trafton D, Wang J, Niu N, Yuan C . Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. Chronic Dis Transl Med. 2020; 6(1):6-17. PMC: 7096327. DOI: 10.1016/j.cdtm.2020.01.002. View

Kurlinkus B, Ger M, Kaupinis A, Jasiunas E, Valius M, Sileikis A . CEACAM6's Role as a Chemoresistance and Prognostic Biomarker for Pancreatic Cancer: A Comparison of CEACAM6's Diagnostic and Prognostic Capabilities with Those of CA19-9 and CEA. Life (Basel). 2021; 11(6). PMC: 8226832. DOI: 10.3390/life11060542. View

Martinez-Bosch N, Vinaixa J, Navarro P . Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy. Cancers (Basel). 2018; 10(1). PMC: 5789356. DOI: 10.3390/cancers10010006. View

Jang J, Hajdu C, Liot C, Miller G, Dustin M, Bar-Sagi D . Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer. Cell Rep. 2017; 20(3):558-571. PMC: 5649374. DOI: 10.1016/j.celrep.2017.06.062. View

Brat D, Bellail A, Van Meir E . The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol. 2005; 7(2):122-33. PMC: 1871893. DOI: 10.1215/S1152851704001061. View

Blogowski W, Deskur A, Budkowska M, Salata D, Madej-Michniewicz A, Dabkowski K . Selected cytokines in patients with pancreatic cancer: a preliminary report. PLoS One. 2014; 9(5):e97613. PMC: 4029741. DOI: 10.1371/journal.pone.0097613. View

Feng L, Qi Q, Wang P, Chen H, Chen Z, Meng Z . Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer. J Int Med Res. 2018; 46(12):5228-5236. PMC: 6300928. DOI: 10.1177/0300060518800588. View

Di Sebastiano P, di Mola F, di Febbo C, Baccante G, Porreca E, Innocenti P . Expression of interleukin 8 (IL-8) and substance P in human chronic pancreatitis. Gut. 2000; 47(3):423-8. PMC: 1728055. DOI: 10.1136/gut.47.3.423. View

10.

Azizian A, Ruhlmann F, Krause T, Bernhardt M, Jo P, Konig A . CA19-9 for detecting recurrence of pancreatic cancer. Sci Rep. 2020; 10(1):1332. PMC: 6987233. DOI: 10.1038/s41598-020-57930-x. View

11.

Hernandez D, Wagner F, Hernandez-Villafuerte K, Schlander M . Economic Burden of Pancreatic Cancer in Europe: a Literature Review. J Gastrointest Cancer. 2022; 54(2):391-407. PMC: 10435615. DOI: 10.1007/s12029-022-00821-3. View

12.

Xu C, Jun E, Okugawa Y, Toiyama Y, Borazanci E, Bolton J . A Circulating Panel of circRNA Biomarkers for the Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma. Gastroenterology. 2023; 166(1):178-190.e16. PMC: 10843014. DOI: 10.1053/j.gastro.2023.09.050. View

13.

Kawai M, Fukuda A, Otomo R, Obata S, Minaga K, Asada M . Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. Br J Cancer. 2024; 131(7):1158-1168. PMC: 11442445. DOI: 10.1038/s41416-024-02794-5. View

14.

Qazi B, Tang K, Qazi A . Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis. Int J Inflam. 2012; 2011:908468. PMC: 3253461. DOI: 10.4061/2011/908468. View

15.

Song J, Sokoll L, Pasay J, Rubin A, Li H, Bach D . Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer. Cancer Epidemiol Biomarkers Prev. 2018; 28(1):174-182. PMC: 6324978. DOI: 10.1158/1055-9965.EPI-18-0483. View

16.

Rawla P, Sunkara T, Gaduputi V . Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019; 10(1):10-27. PMC: 6396775. DOI: 10.14740/wjon1166. View

17.

Kim H, Kang K, Shin Y, Byun Y, Han Y, Kwon W . Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2020; 12(6). PMC: 7352313. DOI: 10.3390/cancers12061443. View

18.

Ebrahimi B, Tucker S, Li D, Abbruzzese J, Kurzrock R . Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer. 2004; 101(12):2727-36. DOI: 10.1002/cncr.20672. View

19.

Chen L, Fan J, Chen H, Meng Z, Chen Z, Wang P . The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. Sci Rep. 2014; 4:5911. PMC: 4118151. DOI: 10.1038/srep05911. View

20.

Robinson S, Rasch S, Beer S, Valantiene I, Mickevicius A, Schlaipfer E . Systemic inflammation contributes to impairment of quality of life in chronic pancreatitis. Sci Rep. 2019; 9(1):7318. PMC: 6513859. DOI: 10.1038/s41598-019-43846-8. View